RVX000222

Phase 2Small molecule

RResverlogix Corp

RVX000222 is one of 57 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Fabry DiseaseActive, not recruiting

Coronary Artery DiseasePhase 2

Active, not recruiting

Fabry DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

223 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

Leqvio

Novartis

Phase 3

2 2

Vanrafia

Novartis

Phase 3

1 3

Byetta

Dalcetrapib

1 5

Repatha

Amgen

Preclinical

3 6

Praluent

Regeneron

Preclinical

3 7

Clopidogrel and Aspirin

Chong Kun Dang Pharmaceutical

Phase 3

1 8

Lexiscan

Astellas

Preclinical

2 9

Neulasta

Amgen

Preclinical

1 10

Nicorette

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

Terminated·RResverlogix Corp·Phase 2·NCT01863225·13 enrolled

Coronary Artery Disease1 trial

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Completed·RResverlogix Corp·Phase 2·NCT01058018·299 enrolled

Intravascular Ultrasound1 trial

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

Completed·RResverlogix Corp·Phase 2·NCT01067820·324 enrolled

Lip1 trial

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

Completed·RResverlogix Corp·Phase 2·NCT01423188·176 enrolled

Fabry Disease1 trial

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

Withdrawn·RResverlogix Corp·Phase 1/2·NCT03228940

2 more indications

Cholesterol1 trial

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Completed·RResverlogix Corp·Phase 1/2·NCT00768274·72 enrolled

PreDiabetes1 trial

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Completed·RResverlogix Corp·Phase 2·NCT01728467·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for RVX000222. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RVX000222 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RVX000222. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Resverlogix Corp company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RResverlogix Corp

RVX000222

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyslipidemia1 trial

Coronary Artery Disease1 trial

Intravascular Ultrasound1 trial

Lip1 trial

Fabry Disease1 trial

Cholesterol1 trial

PreDiabetes1 trial

References

Drug Info

Quick Facts

Related News